Table 2.

Major comorbidities of the study population

	Rotarex®	Lysis	Rotarex®+lysis
Ischemic cardiac disease	44.5% (65/146)	39.3% (11/28)	46.4% (13/28)
Arterial hypertension	75.3% (110/146)	78.6% (22/28)	78.6% (22/28)
Diabetes mellitus	32.2% (47/146)	28.6% (8/28)	50% (14/28)
Smoking	63.7% (93/146)	60.7% (17/28)	67.9% (19/28)
Kidney failure (III–V)	Stadium III 17.8% (26/146)	Stadium III 21.4% (6/28)	Stadium III 10.7% (3/28)
	Stadium IV 3.4% (5/146)	Stadium IV 3.6% (1/28)	Stadium IV 10.7% (3/28)
	Stadium V 2.1% (3/146)	Stadium V 0	Stadium V 0
Hyperlipidemia	36.9% (54/146)	39.2% (11/28)	35.7% (10/28)

Note: P-values >0.05.